股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創醫療科學有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00853 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總 ...

Core Viewpoint - MicroPort Medical (00853) has seen a significant increase in stock price, rising 5.1% to HKD 16.08, with a trading volume of HKD 267 million, following the announcement of a restructuring in its cardiac rhythm management business [1] Group 1: Business Restructuring - MicroPort Medical announced the restructuring of its cardiac rhythm management business, with its subsidiary MicroPort Cardiac Rhythm Management planning to merge with CRM Cayman [1] - Market analysts suggest that this merger aims to alleviate the pressure of meeting listing standards for the cardiac rhythm business [1] - JPMorgan indicated that the successful completion of this transaction would help eliminate significant uncertainties that have been troubling the company [1] Group 2: Strategic Partnerships - The company previously introduced Shanghai Industrial, a state-owned enterprise, as a strategic shareholder [1] - According to Guotai Junan Securities, Shanghai Industrial's capital, backed by its state-owned background and industrial resources, is expected to support the group's core business expansion and potential strategic acquisitions [1] - This partnership aims to enhance corporate governance and facilitate continuous innovation, high-quality development, and scale improvement for the group [1]

Core Viewpoint - MicroPort Medical (00853) has seen a 5.1% increase in stock price, reaching HKD 16.08, with a trading volume of HKD 267 million, following the announcement of a restructuring in its cardiac rhythm management business [1] Group 1: Business Restructuring - MicroPort Medical announced the merger of its subsidiary, MicroPort Cardiac Rhythm Management (CRM) Cayman, as part of a restructuring effort [1] - The merger aims to alleviate the pressure of meeting the "listing performance" targets associated with the cardiac rhythm business [1] Group 2: Market Reactions - Market analysts, including those from JPMorgan, indicated that the successful completion of the transaction would help eliminate significant uncertainties that have been troubling the company [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to enhance the company's core business expansion and potential strategic acquisitions [1] Group 3: Strategic Support - The state-owned background of Shanghai Industrial is anticipated to provide valuable industry resources and support for the company's governance and innovation efforts [1] - The partnership is expected to facilitate high-quality development and scale enhancement for the group [1]

Core Viewpoint - MicroPort Medical (00853) has seen a nearly 5% increase in stock price, currently trading at 15 HKD, with a transaction volume of 86.87 million HKD, following the announcement of a restructuring in its cardiac rhythm management business [1] Group 1: Business Restructuring - MicroPort Medical announced the merger of its subsidiary MicroPort Cardiac Rhythm Management (CRM) with CRM Cayman, which will become a wholly-owned subsidiary post-merger [1] - The merger aims to alleviate the pressure of meeting the "listing target" for the cardiac rhythm business, as noted by market analysts [1] Group 2: Market Reactions and Analyst Insights - JPMorgan expressed that the successful completion of the transaction would help eliminate significant uncertainties that have been troubling the company [1] - Bank of America Securities highlighted the strategic partnership with Shanghai Industrial, a state-owned enterprise, which is expected to support the company's financial and business development [1] Group 3: Future Profitability and Growth - The bank anticipates that through cost control and the disposal of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to diversify domestic market risks and provide long-term growth visibility [1]

Core Viewpoint - MicroPort Medical (00853) has seen a nearly 5% increase in stock price, currently trading at 15 HKD, with a transaction volume of 86.87 million HKD. The company announced a restructuring of its cardiac rhythm management business, which is expected to alleviate pressure related to the "listing performance" gamble [1]. Group 1: Business Restructuring - MicroPort Medical's subsidiary, MicroPort Cardiac Rhythm Management (CRM), plans to merge with CRM Cayman, which will become a wholly-owned subsidiary post-merger [1]. - The merger is aimed at resolving uncertainties that have been a significant concern for the company [1]. Group 2: Market Analysis - JPMorgan has indicated that the successful completion of the transaction will help eliminate major uncertainties that have been affecting the company [1]. - Bank of America Securities has noted that the introduction of a state-owned enterprise, Shanghai Industrial, as a strategic shareholder will support the company's financial and business development [1]. Group 3: Financial Outlook - The bank anticipates that through cost control and the disposal of non-core assets, the company could achieve profitability by the first half of 2026 [1]. - Rapid growth in overseas business is expected to diversify domestic market risks and provide long-term growth visibility [1].

Core Viewpoint - MicroPort Medical (00853) is restructuring its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical announced the merger of its subsidiary MicroPort Cardiac Rhythm Management (CRM) with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to support the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1]

Core Viewpoint - MicroPort Medical (00853) is restructuring its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical announced the merger of its subsidiary MicroPort Cardiac Rhythm Management (CRM) with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to support the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - The rapid growth of overseas business is expected to diversify domestic market risks and provide long-term growth visibility [1]

Core Viewpoint - MicroPort Medical (00853) has announced a restructuring of its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical's subsidiary, MicroPort Cardiac Rhythm Management (CRM), plans to merge with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to bolster the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1]

Group 1 - The company announced the resignation of Mr. Haiteng Bai as non-executive director, honorary chairman, and member of the strategic committee effective September 30, 2025, to dedicate more time to other business activities [1] - Mr. Norihiro Adachi also resigned as non-executive director and member of the audit committee for similar reasons [1] - Dr. Gu Feng has been appointed as a non-executive director and member of the nomination and remuneration committees [1] Group 2 - Dr. Men Qingbing has been appointed as a non-executive director, member of the audit committee, and chairman of the strategic committee [1] - Dr. Chang Zhaohua is no longer a member of the remuneration committee and chairman of the strategic committee [1] - Mr. Zhou Jia Hong has been appointed as a member of the nomination committee [1]

Core Viewpoint - MicroPort Medical (00853.HK) announced the resignation of two non-executive directors, which may impact the company's strategic direction and governance structure [1] Group 1 - Taisuke Shiratani resigned as non-executive director, honorary chairman, and member of the company's strategic committee to focus more on other business activities [1] - Norihiro Adachi resigned as non-executive director and member of the company's audit committee for similar reasons [1]